LFCR SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES LIFECORE BIOMEDICAL, INC.
Ademi LLP announced an investigation into whether Lifecore Biomedical's proposed acquisition by Webster Equity Partners fairly values public shareholders. Lifecore shareholders are set to receive $6.28 per share in a transaction valued at up to $663.7 million; the firm is also probing insider change-of-control benefits and restrictions on competing bids.
Key figures
- Deal Value Usd
- $663.7 million
- Per share price
- $6.28
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.